MCID: HYP083
MIFTS: 54

Hypopituitarism

Categories: Endocrine diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hypopituitarism

MalaCards integrated aliases for Hypopituitarism:

Name: Hypopituitarism 11 19 75 53 5 43 14 16 71 31 33
Pituitary Insufficiency 11 19
Pituitary Hypofunction 11 33
Deficient Secretion of One or More Pituitary Hormones 33
Deficient Secretion of All Pituitary Hormones 33
Postpartum Panhypopituitary Syndrome 33
Anterior Pituitary Insufficiency 33
Anterior Pituitary Hypofunction 33
Prepubertal Panhypopituitarism 33
Pituitary Hypoadrenocorticism 33
Pituitary Hormone Deficiency 11
Pituitary Gland Hypofunction 33
Pituitary Insufficiency Nos 33
Panhypopituitarism Syndrome 33
Postpartum Hypopituitarism 33
Hyposomatotropic Dwarfism 33
Hypophyseal Short Stature 33
Hypopituitarism Syndrome 33
Juvenile Hypopituitarism 33
Primary Hypopituitarism 33
Pituitary Short Stature 33
Hypopituitary Dwarfism 33
Hypopituitary Cachexia 33
Secondary Hypogonadism 33
Pituitary Hypogonadism 33
Hypophyseal Dystrophy 33
Pituitary Infantilism 33
Pituitary Deficiency 33
Hypophyseal Dwarfism 33
Prepubertal Dwarfism 33
Pituitary Dwarfism 33
Pituitary Cachexia 33
Pituitary Failure 33
Hypohypophysism 33
Subpituitarism 33

Classifications:



External Ids:

Disease Ontology 11 DOID:9406
MeSH 43 D007018
NCIt 49 C62591
SNOMED-CT 68 74728003
ICD10 31 E23 E23.0
UMLS 71 C0020635

Summaries for Hypopituitarism

GARD: 19 Hypopituitarism occurs when the body has low levels of certain hormones made by the pituitary gland. The pituitary gland normally makes several hormones (including growth hormone, thyroid stimulating hormone, adrenocorticotropic hormone, prolactin, follicle stimulating hormone and luteinizing hormone, vasopressin, and oxytocin). These hormones are important for directing body growth and development, and for regulating blood pressure and metabolism. Symptoms of this condition vary and depend on which hormones are affected.

MalaCards based summary: Hypopituitarism, also known as pituitary insufficiency, is related to combined pituitary hormone deficiencies, genetic forms and culler-jones syndrome. An important gene associated with Hypopituitarism is PROP1 (PROP Paired-Like Homeobox 1), and among its related pathways/superpathways are Signal Transduction and G-Beta Gamma Signaling. The drugs Testosterone and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and brain, and related phenotypes are nervous system and homeostasis/metabolism

Disease Ontology: 11 A pituitary gland disease characterized by the decreased secretion of one or more of the eight hormones normally produced by the pituitary gland.

Wikipedia: 75 Hypopituitarism is the decreased (hypo) secretion of one or more of the eight hormones normally produced... more...

Related Diseases for Hypopituitarism

Diseases related to Hypopituitarism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1071)
# Related Disease Score Top Affiliating Genes
1 combined pituitary hormone deficiencies, genetic forms 32.9 PROP1 POU1F1 LHX4 HESX1 GLI2
2 culler-jones syndrome 32.5 LHX4 HESX1 GLI2
3 pallister-hall syndrome 32.4 LHX4 HESX1 GLI2
4 sheehan syndrome 32.0 TRH PROP1 PRL POU1F1 POMC LHX4
5 tsh producing pituitary tumor 31.9 PRL POMC
6 growth hormone deficiency 31.8 SOX3 HESX1 GH1
7 isolated growth hormone deficiency 31.8 SOX3 PROP1 POU1F1 LHX4 LHX3 IGF1
8 pituitary hormone deficiency, combined, 2 31.5 TRH SOX3 PROP1 PRL POU1F1 POMC
9 diabetes insipidus 31.5 PRL POMC INS GH1 CRH
10 premature ovarian failure 7 31.5 POMC GH1 CRH
11 septooptic dysplasia 31.4 TRH SOX3 PROP1 PRL POU1F1 POMC
12 central diabetes insipidus 31.4 TRH PRL POMC IGF1 GNRH1 GH1
13 pituitary tumors 31.3 PROP1 PRL IGF1 GH1
14 optic nerve hypoplasia, bilateral 31.0 SOX3 POMC HESX1
15 hypogonadism 31.0 SHBG PROP1 PRL POMC LEP INS
16 penis agenesis 30.9 IGFBP3 GNRH1
17 hypothyroidism, congenital, nongoitrous, 4 30.8 PROP1 PRL POU1F1 POMC IGF1 GH1
18 graves disease 1 30.8 TRH SHBG POMC INS
19 adenoma 30.8 TRH PRL POU1F1 POMC IGF1 GHRH
20 hypoglycemia 30.8 TRH PRL POMC LEP INS IGFBP3
21 pituitary adenoma 30.8 TRH PRL POU1F1 POMC IGF1 GNRH1
22 inappropriate adh syndrome 30.7 PRL POMC CRH
23 empty sella syndrome 30.7 TRH PROP1 PRL POU1F1 POMC LHX3
24 hyperprolactinemia 30.7 TRH SHBG PRL POMC INS IGF1
25 isolated growth hormone deficiency, type ia 30.6 PROP1 IGFBP3 IGF1 GHRH GH1
26 galactorrhea 30.6 PRL IGF1
27 pituitary apoplexy 30.6 TRH PRL POMC INS IGF1 GNRH1
28 craniopharyngioma 30.6 TRH PROP1 PRL POU1F1 INS IGF1
29 hypogonadotropic hypogonadism 30.6 SOX3 SHBG PROP1 PRL POMC LHX4
30 intracranial hypertension 30.6 PRL POMC HSD11B1
31 holoprosencephaly 30.6 SOX3 PROP1 POU1F1 LHX4 LHX3 HESX1
32 pituitary hypoplasia 30.6 SOX3 PROP1 PRL POU1F1 POMC LHX4
33 isolated growth hormone deficiency, type ii 30.6 SOX3 PROP1 POU1F1 IGF1 HESX1 GHRH
34 turner syndrome 30.6 SHBG LEP INS IGFBP3 IGF1 GH1
35 isolated growth hormone deficiency type iii 30.6 SOX3 HESX1
36 cavernous sinus thrombosis 30.6 POMC INS
37 insulin-like growth factor i 30.5 SHBG PRL LEP INS IGFBP3 IGF1
38 acth deficiency, isolated 30.5 TRH PROP1 PRL POU1F1 POMC LHX4
39 adult syndrome 30.5 POMC LEP INS IGF1 CRH
40 pituitary gland disease 30.5 TRH SOX3 PROP1 PRL POU1F1 POMC
41 goiter 30.4 TRH SHBG PRL INS IGF1
42 type 1 diabetes mellitus 30.4 LEP INS IGFBP3 IGF1 GH1
43 kallmann syndrome 30.4 SOX3 PROP1 PRL POU1F1 POMC LHX4
44 amenorrhea 30.4 TRH SHBG PRL POMC LEP INS
45 pituitary-dependent cushing's disease 30.4 TRH PRL POMC GHRH GH1 CRH
46 gynecomastia 30.4 SHBG PRL POMC LEP GNRH1
47 adrenal hypoplasia, congenital 30.4 POMC HESX1 GNRH1
48 non-acquired panhypopituitarism 30.4 SOX3 PROP1
49 panhypopituitarism, x-linked 30.4 SOX3 LHX4
50 lipid metabolism disorder 30.4 SHBG POMC LEP INS IGF1 HSD11B1

Graphical network of the top 20 diseases related to Hypopituitarism:



Diseases related to Hypopituitarism

Symptoms & Phenotypes for Hypopituitarism

GenomeRNAi Phenotypes related to Hypopituitarism according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 CRH GH1 GHRH GLI2 GNRH1 HESX1
2 no effect GR00402-S-2 10.19 CRH GH1 GLI2 GNRH1 HESX1 HSD11B1

MGI Mouse Phenotypes related to Hypopituitarism:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.49 CRH GH1 GHRH GLI2 GNRH1 HESX1
2 homeostasis/metabolism MP:0005376 10.39 CRH GH1 GHRH GLI2 GNRH1 HSD11B1
3 endocrine/exocrine gland MP:0005379 10.35 CRH GH1 GHRH GLI2 GNRH1 HESX1
4 growth/size/body region MP:0005378 10.33 CRH GH1 GHRH GLI2 GNRH1 HESX1
5 liver/biliary system MP:0005370 10.18 CRH GH1 GHRH GNRH1 HSD11B1 IGFBP3
6 behavior/neurological MP:0005386 10.13 CRH GH1 GHRH GLI2 HSD11B1 IGFBP3
7 adipose tissue MP:0005375 10.11 CRH GH1 GHRH HSD11B1 IGF1 IGFBP3
8 renal/urinary system MP:0005367 10.1 CRH GH1 GNRH1 IGF1 INS LEP
9 reproductive system MP:0005389 9.93 GH1 GHRH GLI2 GNRH1 IGF1 INS
10 respiratory system MP:0005388 9.91 CRH GH1 GLI2 HESX1 HSD11B1 IGF1
11 skeleton MP:0005390 9.7 CRH GHRH GLI2 GNRH1 IGF1 IGFBP3
12 integument MP:0010771 9.32 CRH GLI2 GNRH1 HSD11B1 IGF1 IGFBP3

Drugs & Therapeutics for Hypopituitarism

Drugs for Hypopituitarism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Testosterone Approved, Investigational Phase 4 58-22-0 5408 6013
2
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
3
Tetracosactide Approved Phase 4 16960-16-0 16133802 16129617
4
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
5
Methyltestosterone Approved Phase 4 58-18-4 6010
6
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0 21873174 65157
7
Testosterone enanthate Approved Phase 4 315-37-7 9416
8
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
9
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
10
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
11
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
12
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
13
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
14 Hormones Phase 4
15 Androgens Phase 4
16 Anti-Inflammatory Agents Phase 4
17 Epinephryl borate Phase 4
18 Analgesics Phase 4
19 Antirheumatic Agents Phase 4
20 Cyclooxygenase Inhibitors Phase 4
21 Anti-Inflammatory Agents, Non-Steroidal Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Antineoplastic Agents, Hormonal Phase 4
24 Anabolic Agents Phase 4
25 Testosterone 17 beta-cypionate Phase 4
26 Pharmaceutical Solutions Phase 4
27 Corticotropin-Releasing Hormone Phase 4
28 Hormone Antagonists Phase 4
29 Hydrocortisone 17-butyrate 21-propionate Phase 4
30 Arginine Vasopressin Phase 4
31 Hypoglycemic Agents Phase 4
32 Glucagon-Like Peptide 1 Phase 4
33 Incretins Phase 4
34 Anti-Obesity Agents Phase 4
35
Anastrozole Approved, Investigational Phase 2, Phase 3 120511-73-1 2187
36
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
37
Clomifene Approved, Investigational Phase 3 911-45-5 2800
38
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
39
Enclomiphene Investigational Phase 3 15690-57-0 1548953
40 Insulin, Globin Zinc Phase 3
41
Insulin Phase 3
42 Mitogens Phase 3
43 Estrogens Phase 3
44 Estrogen Receptor Antagonists Phase 2, Phase 3
45 Estrogen Antagonists Phase 2, Phase 3
46 Aromatase Inhibitors Phase 2, Phase 3
47 Estrogen Receptor Modulators Phase 3
48 Zuclomiphene Phase 3
49 Citrate Phase 3
50 Selective Estrogen Receptor Modulators Phase 3

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 Physiologic Testosterone Replacement in Women With Hypopituitarism Completed NCT00144391 Phase 4 Transdermal Testosterone gel
2 Comparison of an Incremental Weight-Based Dose Regimen With an Individualized Dosage Adjusted According to the IGF-I Response in Adults With Growth Hormone Deficiency Completed NCT00490191 Phase 4 Somatropin
3 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Completed NCT00851942 Phase 4 Synacthen (Tetracosactrin)
4 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia Completed NCT00140413 Phase 4 Nutropin AQ
5 Acute Neuroendocrine Response to Intravenous Infusion of Diclofenac Sodium Completed NCT05188131 Phase 4 Intravenous Infusion of Diclofenac Sodium;Intravenous Infusion of Placebo
6 A Randomised, Controlled, Crossover Study: Treatment With Thyroxin Compared to Thyroxin + Triiodothyronin in Patients With Secondary Hypothyroidism Completed NCT00360074 Phase 4 Thyroxin, Triiodothyronine
7 Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes Completed NCT05206149 Phase 4 Intranasal glugagon;Intranasal placebo
8 Phase 4 Study That Compares the High Density Lipoprotein Cholesterol (HDL) Cholesterol Subgroups of the Patients With Congenital Hypogonadotrophic Hypogonadism With That of the Healthy Control Subjects, and Investigates the Effect of Testosterone Treatment on HDL Subgroups. Completed NCT01454011 Phase 4 Testosteron 250mg injection;Testosterone 50mg transdermal application
9 Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study) Recruiting NCT04897802 Phase 4 Experimental: GLP1-RA (exenatide) administration;Control: Placebo administration
10 Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept Physiopathological Study (CRH Study) Recruiting NCT04902235 Phase 4 Experimental: CRH administration;Control: Placebo administration
11 Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults Completed NCT01007071 Phase 3 Human Growth Hormone (1-134);Placebo
12 Double-blind Trial Investigating the Safety and Efficacy of the Inhibitor Anastrozole (ARIMIDEX) in Delaying Epiphyseal Fusion and Increasing Height Potential of Adolescent Males With Growth Hormone (GH) Deficiency Completed NCT00133354 Phase 2, Phase 3 Arimidex (Anastrozole);Placebo;Growth Hormone
13 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Open-Label, Active-Controlled Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism Completed NCT00962637 Phase 3 Androxal;AndroGel;Placebo
14 A 12 Month, Single Blind, Placebo Controlled, Phase III Study to Assess the Effects of Enclomiphene Citrate Treatment On Bone Mineral Density in Men With Secondary Hypogonadism Completed NCT01619683 Phase 3 enclomiphene citrate;Placebo
15 An Open-Label, Multiple Center Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism Who Completed ZA-003 Completed NCT01067365 Phase 3 Androxal
16 An Open Label, 6 Month Phase III Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism Completed NCT01739582 Phase 3 Androxal
17 An Open Label, Escalating Dose, 6 Month Phase III Safety Study Of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism Completed NCT01534208 Phase 3 Androxal
18 A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% Completed NCT01993212 Phase 3 Androxal 12.5 mg or 25 mg;AndroGel 1.62%;Placebo Capsules;Placebo Gel
19 A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-Term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men Completed NCT00467870 Phase 3 Testosterone Undecanoate 750 mg;Testosterone Undecanoate 1000 mg
20 A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% Completed NCT01993225 Phase 3 Androxal 12.5 mg/25 mg;Placebo Capsules;AndroGel 1.62%;Placebo Gel
21 A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration Completed NCT01739595 Phase 3 enclomiphene citrate;Placebo
22 A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration Completed NCT01532414 Phase 3 Androxal;Placebo
23 A Phase IIIb, Prospective, Multicenter, Randomized, Open-label Study to Determine the Safety and Efficacy of Two Different Dosing Regimens of Saizen® (Recombinant Human Growth Hormone (r-hGH), Using Cool.Click™ in Subjects With Childhood-onset Growth Hormone Deficiency During the Adolescent Transition Phase (CATS) Completed NCT00109733 Phase 3
24 Somatropin (Norditropin) in Children With Growth Failure Associated With ICF Deficiency. Completed NCT00102817 Phase 3 somatropin
25 An 8-Week Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men Unknown status NCT02443090 Phase 2 fispemifene
26 Will Testosterone and Growth Hormone Improve Bone Structure? Completed NCT00080483 Phase 2 Testosterone plus somatropin;testosterone
27 A Randomized, Open-Label, Fixed Dose, Active-Control, Multi-Center Phase IIB Study to Evaluate Fertility in Men With Secondary Hypogonadism, Comparing Androxal® to a Topical Testosterone in Men Previously Treated With Topical Testosterone. Completed NCT00706719 Phase 2 25 mg Androxal;Testim 1%
28 A Study to Evaluate the Efficacy of Androxal® in Improving Glycemic Control in Men With Secondary Hypogonadism or Adult-onset Idiopathic Hypogonadotropic Hypogonadism (AIHH) and Type 2 Diabetes Mellitus With Sub-Optimum Treatment Completed NCT01191320 Phase 2 Placebo;Androxal
29 A One Year Open Label Study of Androxal in the Treatment of Secondary Hypogonadism in Men Who Have Completed Protocol ZA-203 Completed NCT01386567 Phase 2 Androxal (enclomiphene citrate);Testim (topical testosterone)
30 A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism Completed NCT01270841 Phase 2 Placebo;topical testosterone;Androxal
31 A Multi-Center, Open-Label, Observational Study of Testosterone Gel (1%) in the Treatment of Adolescent Boys With Hypogonadism Completed NCT00193661 Phase 2 Testosterone Gel (1%)
32 Pharmacokinetic Study to Determine Time to Steady-state of an Oral Testosterone Undecanoate Formulation in Hypogonadal Men. Completed NCT00911586 Phase 2 Testosterone undecanoate
33 A Randomized, Single Blind, Multi-Center Phase II Study to Evaluate the Effect of Three Different Doses of Androxal and AndroGel on 24-Hour Luteinizing Hormone and Testosterone in Normal Healthy Men Completed NCT01386606 Phase 2 Androxal (enclomiphene citrate);Testosterone
34 Interventional Study of Growth Hormone Replacement Therapy in Retired Professional Football Players With Growth Hormone Deficiency Recruiting NCT04121780 Phase 2
35 A Phase 1, Randomised, Open-label, 2-cohort, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Native Oral Testosterone Formulation (DITEST) in the Fed and Fasted State and Compared to Testosterone Undecanoate in Adult Men With Primary or Secondary Hypogonadism Completed NCT02966652 Phase 1 DITEST;Testosterone undecanoate
36 An Open Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Hepatic Function Completed NCT01923870 Phase 1 Androxal 25 mg
37 A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function Completed NCT01923857 Phase 1 Androxal 25 mg
38 An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration Completed NCT02274181 Phase 1 Androxal
39 Pharmacokinetic Evaluation of Testosterone Gel (1%) in Prepubertal Boys of Adolescent Age Completed NCT00193700 Phase 1 Testosterone Gel (1%)
40 Prevalence of Hypopituitarism Following Combat-related Traumatic Brain Injury in a Military Population Unknown status NCT01666964
41 Next Day Early Morning Growth Hormone as Predictor of Pituitary Function After Transsphenoidal Adenomectomy Unknown status NCT03708523
42 Variability of Uterine and Breast Development in Response to Exogenous Oestrogen During Induction of Puberty in Individuals With Hypogonadism. Unknown status NCT02871986 Routine transdermal oestrogen patch
43 Hypopituitarism Following Traumatic Brain Injury or Spontaneous Subarachnoidal Haemorrhages Completed NCT00435006
44 Effects of CRH on the Sleep in Patients With Hypopituitarism Completed NCT00666068
45 TheraDerm Administration in Women With Hypopituitarism Completed NCT00027430 TheraDerm
46 Posttraumatic Hypopituitarism - Incidence, Predictors and Test Validity Completed NCT01028742
47 Lipolytic Effects of GH in Hypopituitary Patients in Vivo: Molecular Mechanisms and Temporal Patterns. Completed NCT02782208 Acipimox;Placebo;GH substitution
48 Prospective Longitudinal Study on Pituitary Functions After TBI and/or SAH Completed NCT00507104
49 Phase 4 Study of Recombinant GH on Intima-Media Thickness at Common Carotids and on Cardiovascular Risk Factors in Hypopituitary Patients Completed NCT00462475 Recombinant Growth Hormone, Genotropin (Pfizer)
50 Effects of Acute Ghrelin Infusion to Growth Hormone Deficient Adults: Growth Hormone and Cortisol Interaction Completed NCT00139945 Human acylated ghrelin

Search NIH Clinical Center for Hypopituitarism

Cochrane evidence based reviews: hypopituitarism

Genetic Tests for Hypopituitarism

Anatomical Context for Hypopituitarism

Organs/tissues related to Hypopituitarism:

MalaCards : Pituitary, Thyroid, Brain, Bone, Breast, Hypothalamus, Liver

Publications for Hypopituitarism

Articles related to Hypopituitarism:

(show top 50) (show all 7403)
# Title Authors PMID Year
1
Comparison of glucose and lipid metabolism and bone mineralization in patients with growth hormone deficiency with and without long-term growth hormone replacement. 53 62
19800640 2010
2
Congenital hypopituitarism: clinico-radiological correlation. 53 62
20020580 2009
3
Heterophilic antibodies may be a cause of falsely low total IGF1 levels. 53 62
19608715 2009
4
Pituitary tumours: pituitary incidentalomas. 53 62
19945030 2009
5
Lack of regulation of 11beta-hydroxysteroid dehydrogenase type 1 during short-term manipulation of GH in patients with hypopituitarism. 53 62
19549748 2009
6
Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register. 53 62
19226273 2009
7
Hyperthyroidism unmasked several years after the medical and radiosurgical treatment of an invasive macroprolactinoma inducing hypopituitarism: a case report. 53 62
19829805 2009
8
[A case of adult-onset idiopathic hypogonadotropic hypogonadism presenting with infertility]. 53 62
19673435 2009
9
Growth without growth hormone and similar dysmorphic features in three patients with sporadic combined pituitary hormone deficiencies. 53 62
19844116 2009
10
Sex steroid replacement for induction of puberty in multiple pituitary hormone deficiency. 53 62
19337185 2009
11
Deficiency of growth hormone in an adult man case of idiopathic adrenocorticotropin deficiency. 53 62
19367057 2009
12
[Diagnosis and treatment of adult growth hormone deficiency (aGHD) resulting from brain injury--role of aGHD]. 53 62
19110756 2008
13
A novel dominant negative mutation of OTX2 associated with combined pituitary hormone deficiency. 53 62
18728160 2008
14
Analysis of mouse models carrying the I26T and R160C substitutions in the transcriptional repressor HESX1 as models for septo-optic dysplasia and hypopituitarism. 53 62
19093031 2008
15
A simple and cost-effective approach to assessment of pituitary adrenocorticotropin and growth hormone reserve: combined use of the overnight metyrapone test and insulin-like growth factor-I standard deviation scores. 53 62
18664544 2008
16
Update on epidemiology, etiology, and diagnosis of adult growth hormone deficiency. 53 62
19020378 2008
17
Diagnostic usefulness of the growth hormone-releasing peptide-2 test as a substitute for the insulin tolerance test in hypopituitarism. 53 62
18493103 2008
18
Heterozygous mutation of HESX1 causing hypopituitarism and multiple anatomical malformations without features of septo-optic dysplasia. 53 62
18852528 2008
19
Novel mutations in LHX3 are associated with hypopituitarism and sensorineural hearing loss. 53 62
18407919 2008
20
Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours. 53 62
18031317 2008
21
Diagnosis of adult GH deficiency. 53 62
17766155 2008
22
Diagnosis of adult GH deficiency. 53 62
18404387 2008
23
An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy. 53 62
17690987 2008
24
[Problems typical for patients with hypopituitarism - a case presentation]. 53 62
18577349 2008
25
Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. 53 62
18057375 2007
26
Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism. 53 62
18057377 2007
27
Molecular analysis of PROP1, PIT1, HESX1, LHX3, and LHX4 shows high frequency of PROP1 mutations in patients with familial forms of combined pituitary hormone deficiency. 53 62
18157385 2007
28
Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism. 53 62
17426086 2007
29
Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. 53 62
19669352 2007
30
[Arterial stiffness in hypopituitary patients with life-long growth hormone deficiency]. 53 62
18030871 2007
31
Acquired prolactin deficiency in patients with disorders of the hypothalamic-pituitary axis. 53 62
17556861 2007
32
GH response to ghrelin in subjects with congenital GH deficiency: evidence that ghrelin action requires hypothalamic-pituitary connections. 53 62
17389459 2007
33
HESX1 mutations are an uncommon cause of septooptic dysplasia and hypopituitarism. 53 62
17148560 2007
34
Hormonal, pituitary magnetic resonance, LHX4 and HESX1 evaluation in patients with hypopituitarism and ectopic posterior pituitary lobe. 53 62
17201807 2007
35
Hypopituitarism oddities: congenital causes. 53 62
18174732 2007
36
Polyalanine expansion mutations in the X-linked hypopituitarism gene SOX3 result in aggresome formation and impaired transactivation. 53 62
17127446 2007
37
Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood. 53 62
17429591 2007
38
Effect of thyroxine replacement on serum IGF-I, IGFBP-3 and the acid-labile subunit in patients with hypothyroidism and hypopituitarism. 53 62
17121519 2006
39
Hypopituitarism in childhood and adolescence following traumatic brain injury: the case for prospective endocrine investigation. 53 62
17062881 2006
40
PROP1 gene analysis in Portuguese patients with combined pituitary hormone deficiency. 53 62
16984240 2006
41
A case of catecholamine and glucocorticoid excess syndrome due to a corticotropin-secreting paraganglioma. 53 62
17102072 2006
42
Serum ghrelin levels are suppressed in hypopituitary patients following insulin-induced hypoglycaemia irrespective of GH status. 53 62
16886962 2006
43
Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. 53 62
16403824 2006
44
Clinical case seminar: a novel LHX3 mutation presenting as combined pituitary hormonal deficiency. 53 62
16394081 2006
45
Hypopituitarism. 53 62
17077946 2006
46
Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. 53 62
16144946 2005
47
[Standardization of DNA extraction with NaCl from oral mucosa cells: application in PROP1 gene study]. 53 62
16544023 2005
48
Duplication of Xq26.2-q27.1, including SOX3, in a mother and daughter with short stature and dyslalia. 53 62
16097007 2005
49
Mutations within the transcription factor PROP1 are rare in a cohort of patients with sporadic combined pituitary hormone deficiency (CPHD). 53 62
15963055 2005
50
[Primary hypothyroidism associated with empty sella turcica and hypopituitarism]. 53 62
16296587 2005

Variations for Hypopituitarism

ClinVar genetic disease variations for Hypopituitarism:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ROBO1 NM_002941.4(ROBO1):c.1400C>T (p.Ala467Val) SNV Uncertain Significance
1338794 GRCh37: 3:78719394-78719394
GRCh38: 3:78670244-78670244

Expression for Hypopituitarism

Search GEO for disease gene expression data for Hypopituitarism.

Pathways for Hypopituitarism

GO Terms for Hypopituitarism

Cellular components related to Hypopituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.32 PRL POMC LEP INS IGFBP3 IGF1
2 extracellular region GO:0005576 10.03 CRH GH1 GHRH GNRH1 IGF1 IGFBP3
3 insulin-like growth factor ternary complex GO:0042567 9.56 IGFBP3 IGF1
4 insulin-like growth factor binding protein complex GO:0016942 9.46 IGFBP3 IGF1
5 endosome lumen GO:0031904 9.1 PRL INS GH1

Biological processes related to Hypopituitarism according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.28 GLI2 IGF1 LEP LHX3 LHX4 PROP1
2 positive regulation of cell population proliferation GO:0008284 10.25 PRL LEP INS IGF1 GLI2 GHRH
3 positive regulation of MAPK cascade GO:0043410 10.16 LEP INS IGFBP3 IGF1
4 cell-cell signaling GO:0007267 10.1 TRH POMC INS GNRH1 GHRH
5 response to nutrient levels GO:0031667 9.97 PRL LEP GH1
6 placenta development GO:0001890 9.97 LHX4 LHX3 LEP
7 lung development GO:0030324 9.97 LHX3 HSD11B1 GLI2 CRH
8 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 9.95 PRL LEP GH1
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.92 GH1 IGF1 INS LEP
10 bone mineralization involved in bone maturation GO:0035630 9.83 LEP IGF1
11 dorsal/ventral pattern formation GO:0009953 9.81 PROP1 LHX3 GLI2
12 somatotropin secreting cell differentiation GO:0060126 9.76 LHX3 PROP1
13 negative regulation of glucagon secretion GO:0070093 9.73 CRH LEP
14 medial motor column neuron differentiation GO:0021526 9.56 LHX4 LHX3
15 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.56 IGFBP3 IGF1 GHRH GH1
16 adenohypophysis development GO:0021984 9.55 PROP1 POU1F1 GHRH
17 pituitary gland development GO:0021983 9.23 SOX3 PROP1 LHX3 HESX1 GLI2

Molecular functions related to Hypopituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.58 TRH PRL POMC LEP INS IGF1
2 peptide hormone receptor binding GO:0051428 9.46 LEP GHRH
3 prolactin receptor binding GO:0005148 9.26 PRL GH1

Sources for Hypopituitarism

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....